Deal Watch: AbbVie Bets On Turnstone’s Cancer Immunotherapy Technology

 
• By Joseph Haas, Lubna Ahmed, John Davis, and Anju Ghangurde

AbbVie takes options on three oncolytic virus immunotherapies under development at Turnstone. Amgen and CytomX swap IP in cancer immunotherapy collaboration, while Nicox and pSivida will team to fight glaucoma and other eye diseases.

DealWatch_1200x675

More from Deals

More from Business